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In this report, we outline the case of a patient who has Ehlers–Danlos Syndrome (EDS) who
received two courses of CyberKnife stereotactic radiosurgery (SRS) for metastatic non-small
cell lung cancer. Patients with EDS have increased blood vessel fragility, and therefore are
subject to increased risk of bleeding. There are no published data regarding the risks of
hemorrhage associated with SRS for intracranial metastases in this patient population. The
patient described in this case report had two courses of SRS for two sites of brain metastases.yberKnife
hlers–Danlos syndrome
She tolerated treatment well, with no acute toxicity and good local control to date. We  have
also  included a discussion of published literature regarding toxicity of intracranial radiation
in  patients with EDS.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. AllD is a 71-year-old woman with a past medical history signiﬁ-
ant for Ehlers–Danlos syndrome (EDS) and tobacco abuse who
resented to her primary care physician with cough and mild
emoptysis. Chest X-ray and CT scan demonstrated an abnor-
ality in the lower lobe of the left lung. A PET scan showed
ildly FDG avid left hilar lymph nodes and a 6.8 cm × 12 cm
eft lower lobe mass abutting the aorta; there was no extra-
horacic disease. Endobronchial ultrasound guided biopsy of
 subcarinal lymph node was positive for adenocarcinoma.
taging brain MRI  revealed a 7 mm ring enhancing lesion in
he anterior right frontal lobe consistent with metastasis.
Approximately 5 years prior to her cancer diagnosis, the
atient was evaluated by a clinical geneticist at our institution
nd diagnosed with hypermobility type EDS. She also has a
istory of EDS-related medical problems, including Raynaud’s
yndrome, subarachnoid hemorrhage, infra-renal abdominal
ortic aneurysm, hypertension, and lower GI bleeding.
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For management of her lung cancer, she received con-
current chemotherapy and external beam radiation therapy.
She initially received carboplatin and paclitaxel, but due to
severe myalgia and arthralgia was switched to carboplatin
and pemetrexed for subsequent cycles. After the completion
of chemoradiotherapy, she was evaluated for consideration of
CyberKnife stereotactic radiosurgery (SRS) for a solitary right
frontal brain metastasis. At that time, the patient denied any
neurologic symptoms. Physical exam did not reveal any focal
neurologic deﬁcits or other abnormalities. Treatment options
for her intracranial disease were discussed, which included
observation, surgical resection with or without adjuvant radi-
ation therapy (whole brain or SRS), whole brain radiation
127599, United States. Tel.: +1 919 966 0400; fax: +1 919 966 7681.
therapy, and CyberKnife SRS. As part of this discussion, the
patient was informed that she may be at higher risk for severe
complications from SRS, including life-threatening intracra-
nial hemorrhage, given her diagnosis of EDS. We  explained
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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that there were no published data evaluating the safety of
CyberKnife SRS in patients with EDS. The patient elected to
proceed with CyberKnife SRS.
She was treated with a single fraction of CyberKnife SRS to
her right frontal brain metastasis. She received a prescription
dose of 20 Gy prescribed to the 81% isodose line. The maxi-
mum dose was 24.6 Gy which occurred within tumor volume.
The conformity index was 1.25 and 97.1% of the tumor vol-
ume  received the prescription dose or higher (see Fig. 1). The
patient tolerated SRS well and had no acute toxicity from treat-
ment. Approximately 3 months later, the patient was seen in
Radiation Oncology clinic for ongoing oncologic surveillance.
A repeat MRI  demonstrated stability of the right frontal metas-
tasis that was treated, with no evidence of new intracranial
metastases.
She returned for repeat brain imaging approximately 6
months after her course of CyberKnife SRS. A brain MRI
demonstrated a new 1 cm metastasis in the left frontal lobe,
as well as interval decrease in the size of the previously
treated right frontal lobe metastasis. Her extra-cranial disease
remained stable. At this time, she did complain of occasional
symptoms of imbalance while walking and difﬁculty with
word-ﬁnding. These symptoms were said to occur several
times per week. She otherwise denied any other neurologic
or focal complaints. Physical exam showed some mild gait
unsteadiness but did not demonstrate focal weakness or any
new neurologic deﬁcits.
We  again discussed treatment options with the patient,
and she elected to proceed with a second course of CyberKnife
SRS to the new metastatic lesion. Her left frontal lobe metas-
tasis was treated with a prescribed dose of 20 Gy to the 83%
isodose line. The maximum dose was 24.1 Gy and occurredr ﬁrst SRS treatment.
within the tumor volume. The conformity index was 1.23 and
100% of the tumor volume received the prescription dose or
higher (see Fig. 2). The dose to the previously treated right
frontal radiosurgical bed was limited to 28 cGy. She tolerated
the procedure well and had no acute toxicity from treatment.
1.  Discussion
Ehlers–Danlos syndrome refers to a heterogeneous group of
inherited connective tissue disorders that are caused by vari-
ous defects in the synthesis of type I or type III collagen. The
nomenclature for types of EDS has evolved over the years, and
was simpliﬁed in 1997 to six major types: (1) hypermobility,
(2) classical, (3) vascular, (4) kyphoscoliosis, (5) athrochalasis,
and (6) dermatosparaxis.2 Vascular EDS (previously known as
Type IV EDS) is inherited in an autosomal dominant fashion
and is caused by a defect in the synthesis of type III colla-
gen. One important clinical characteristic of this defect is the
association with blood vessel fragility, which causes affected
patients to have above-average risk for blood vessel rupture.3
This can manifest as spontaneous rupture of cerebral arteries,
easy skin bruising, and aortic aneurysm. Hypermobility type
EDS, such as that seen in our patient, is a much more  com-
mon  albeit less severe form of this disease.4 Given our patient’s
history of EDS-related gastrointestinal as well as intracranial
bleeding, it is reasonable to assume that she may have an
increased risk of bleeding related to CyberKnife SRS treatment
of intracranial metastatic disease.
To the authors’ knowledge, there are no published data
regarding the risk of acute or late toxicity associated with
CyberKnife SRS in patients with EDS. Holodny et al. reported
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 241–244 243
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None declared.Fig. 2 – Treatment plan
 patient with a presumptive diagnosis of Vascular EDS who
eceived whole brain radiation therapy for breast cancer
etastatic to the brain.5 She received 21 Gy and four months
ater was treated with an additional 10.8 Gy. Both courses of
adiotherapy were tolerated without any acute toxicity. Three
onths after the second treatment, the patient had a general-
zed seizure and died shortly thereafter. Her autopsy revealed
even aneurysms in or near the Circle of Willis, one of which
ad ruptured. All other intracranial vessels were found to be
ormal at autopsy. Interestingly, an MRI  performed prior to
ntracranial radiation therapy did not show any abnormalities
n the vessels of the Circle of Willis.
In vitro studies have shown that there is an increase in colla-
en biosynthesis in cells that are exposed to ionizing radiation
t doses comparable to what is used for therapeutic whole
rain radiation.6 The formation of intimal ﬁbrosis may prevent
he formation of an aneurysm.7 Patients with EDS are at above
verage risk for blood vessel aneurysm and rupture because of
eﬁciencies in the collagen supporting these vessels. Further-
ore,  Holodny et al. hypothesize that patients with Vascular
DS are more  sensitive to blood vessel damage caused by high
oses of ionizing radiation due to the inability to generate a
rotective intimal ﬁbrotic response.5 This might lead one to
e leery of administering high-dose radiosurgery to patients
ith EDS. However, at this time our patient continues to be
ithout symptoms from her treatment.
Although we are unaware of published literature regarding
oxicity of SRS in patients with EDS, Lowell et al. recently pub-
ished a series examining the toxicity of SRS in patients with
ixed connective tissue disease (MCTD).8 In this retrospective
eries, 14 patients with MCTD were treated with Gamma  Knife
adiosurgery (GKRS) for intracranial tumors. No patients weresecond SRS treatment.
reported to have suffered vascular injury or aneurysm related
to GKRS. Despite the different mechanisms underlying vascu-
lar abnormality and weakness between EDS and MCTD, it is
notable that patients with a nominally increased risk of vas-
cular injury were able to tolerate high dose radiosurgery with
no vascular complications.
In summary, we report the case of a patient with Vascular
EDS who was treated with two  courses of CyberKnife SRS for
intracranial metastatic disease. To date, the patient has not
experienced any signiﬁcant treatment related toxicity and has
shown satisfactory local control. The two lesions treated in our
patient were located in the frontal lobe and were not in close
proximity to the Circle of Willis. This case demonstrates that
CyberKnife SRS can be safely administered and effective in
patients with EDS.
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radiosurgery in the treatment of intracranial tumors in
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